Tesofensine CAS 402856-42-2 NS-2330

Payment Terms: T/T,L/C,WU
Trade on HiSupplier, Worry Free Guarantee
Trading safety, secure your money, lower the risk, protect both buyers and suppliers
HiSupplier is a Chinese multinational company in U.S, it helps to coordination and order landing.
More ›
  • Product Details
  • Company Profile
  • Product Reviews
Basic Info.
  • Brand: MOSINTER 
  • Formula: C17H23Cl2NO 
  • Mol. mass: 328.277 g/mol 
  • Content: 99% 
  • Appearance: White or almost white, crystalline powder 
  • CAS: 402856-42-2 
  • Density: 1.162g/cm3 
  • Boiling point: 396.629°C at 760 mmHg 
  • Flashing point: 193.675°C 
  • Model No.: C17H23Cl2NO 
  • Place of Origin: Shandong  
  • Min.Order: 6 Kilogram
  • Means of Transport: Ocean, Air, Land
Supply Capacity
  • Production Capacity: 1000kg/month
  • Packing:According to customer requirements
  • Delivery Date: within 7 days

Tesofensine (CAS:402856-42-2)

Item Specification Result
Appearance White or almost white, crystalline powder Complies

Related substance (HPLC)

Total impurity ≤0.5%

Max single impurity ≤0.1%



Odor  CharacteristicComplies
Assay  99%99.8%
Sieve analysis  100% pass 80 meshComplies

Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of medicine, which is being developed for the treatment of obesity. The right to develop and market tesofensine is held by NeuroSearch, a Danish pharmaceutical company.


Metabolism and t½

Tesofensine has a long half-life of about 9 days (220 h) and is mainly metabolized by cytochrome P4503A4 (CYP3A4) to the N-normethyl-metabolite NS2360.[7][8] NS2360 is the only metabolite detectable in human plasma. It has a longer half-life than tesofensine, i.e. approximately 16 days (374 h) in humans, and has an exposure of 31–34% of the parent compound at steady state. In vivo data indicate that NS2360 is responsible for approximately 6% of the activity of tesofensine. As in animals, the kidney appears to play only a minor role in the clearance of tesofensine in humans (about 15–20%).

Adverse events

In general, the safety profile of tesofensine is similar to currently approved medications for the treatment of obesity. The most commonly reported side effects in the obese population were dry mouth, headache, nausea, insomnia, diarrhoea and constipation. A dose-dependent pattern was observed for dry mouth and insomnia. The overall withdrawal rate due to adverse events in clinical trials in the obese population was 13% with tesofensine and 6% with placebo. Blood pressure and heart rate increases with the therapeutically relevant doses of tesofensine (0.25 mg and 0.5 mg) were 1–3 mmHg and up to 8 bpm, respectively.

Tesofensine very effective for central obesity. Another study shows that low doses of SuoFenXin obesity treatment is safe and effective.


Send message to this supplier
Mr. Fedor
Tel: +86-574-89212210
Mobile: +86-18989305995
Enter between 20 to 3,000 chatacters.
Contact Method
Guangbo Center Office 2001, YinXianDaDao 1357, Ningbo, Zhejiang, China (Mainland) / 315100
Fax: +86-574-89212215
Didn't find what you're looking for? Post Buying Lead or contact our customer service specialist for help!
Buyer Help Center